Clinical Characteristics and Outcome of COVID-19 in Turkish Hematological Malignancy Patients
View/ Open
Date
2022 şubatAuthor
CİVRİZ BOZDAĞ SİNEMCENGİZ SEVAL GÜLDANE
YÖNAL HİNDİLERDEN İPEK
HİNDİLERDEN FEHMİ
ANDIÇ NESLİHAN
BAYDAR MUSTAFA
AYDIN KAYNAR LALE
TOPRAK SELAMİ KOÇAK
GÖKSOY HASAN SAMİ
BALIK AYDIN BERRİN
DEMİRCİ UFUK
CAN FERDA
ÖZKOCAMAN VİLDAN
GÜNDÜZ EREN
GÜVEN ZEYNEP TUĞBA
ÖZKURT ZÜBEYDE NUR
DEMİRCİOĞLU SİNAN
BEKSAÇ MERAL
İNCE İDRİS
YILMAZ UMUT
EROĞLU KÜÇÜKDİLER AYŞE HİLAL
ABİSHOV ELGÜN,
YAVUZ BORAN
ATAŞ ÜNAL
MUTLU YAŞA GÜL
BAŞ VOLKAN
ÖZKALEMKAŞ FAHİR
ÜSKÜDAR TEKE HAVA
GÜRSOY VİLDAN
ÇELİK SERHAT
ÇİFTÇİLER RAFİYE
YAĞCI ABDULLAH MÜNCİ
TOPÇUOĞLU PERVİN
ÇENELİ ÖZCAN
ABBASOV HAMZA
SELİM CEM
AR MUHLİS CEM
YÜCEL ORHAN KEMAL
SADRİ SEVİL
ALBAYRAK YAŞAR CANAN
DEMİR AHMET MUZAFFER
GÜLER NİL
KEKLİK MUZAFFER
TERZİ HATİCE
DOĞAN ALİ
YEGİN ZEYNEP ARZU
KURT YÜKSEL MELTEM
SADRİ SOĞOL
YAVAŞOĞLU İRFAN
Hüseyin Saffet Beköz
Tekin Aksu
Senem Maral
Veysel Erol
Leylagül Kaynar
İLHAN OSMAN
BOLAMAN ALİ ZAHİT
SEVİNDİK ÖMÜR GÖKMEN
AKYAY ARZU
ÖZCAN MUHİT
GÜRMAN GÜNHAN
CANGÜL ÜNAL ŞULE
YAVUZ YASEMİN
KÜÇÜKKAYA DİZ REYHAN
ÖZSAN GÜNER HAYRİ
Metadata
Show full item recordCitation
Sinem Civriz Bozdağ, Güldane Cengiz Seval, İpek Yönal Hindilerden, Fehmi Hindilerden, Neslihan Andıç, Mustafa Baydar, Lale Aydın Kaynar,et al. Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies. Turk J Haematol. 2022 Feb 23;39(1):43-54.Abstract
Objective: Patients with solid malignancies are more vulnerable
to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
infection than the healthy population. The outcome of SARS-CoV-2
infection in highly immunosuppressed populations, such as in patients
with hematological malignancies, is a point of interest. We aimed to
analyze the symptoms, complications, intensive care unit admissions,
and mortality rates of patients with hematological malignancies
infected with SARS-CoV-2 in Turkey.
Materials and Methods: In this multicenter study, we included
340 adult and pediatric patients diagnosed with SARS-CoV-2 from
March to November 2020. Diagnosis and status of primary disease,
treatment schedules for hematological malignancies, time from last
treatment, life expectancy related to the hematological disease, and
comorbidities were recorded, together with data regarding symptoms,
treatment, and outcome of SARS-CoV-2 infection.
Results: Forty four patients were asymptomatic at diagnosis of SARS CoV-2 infection. Among symptomatic patients, fever, cough, and
dyspnea were observed in 62.6%, 48.8%, and 41.8%, respectively. Sixty nine (20%) patients had mild SARS-CoV-2 disease, whereas moderate,
severe, and critical disease was reported in 101 (29%), 71 (20%), and 55
(16%) patients, respectively. Of the entire cohort, 251 (73.8%) patients
were hospitalized for SARS-CoV-2. Mortality related to SARS-CoV-2
infection was 26.5% in the entire cohort; this comprised 4.4% of those
patients with mild disease, 12.4% of those with moderate disease,
and 83% of those with severe or critical disease. Active hematological
disease, lower life expectancy related to primary hematological disease,
neutropenia at diagnosis of SARS-CoV-2, ICU admission, and first-line
therapy used for coronavirus disease-2019 treatment were found to be
related to higher mortality rates. Treatments with hydroxychloroquine
alone or in combination with azithromycin were associated with a
higher rate of mortality in comparison to favipiravir use.
Conclusion: Patients with hematological malignancy infected with
SARS-CoV-2 have an increased risk of severe disease and mortality.